ER+ BC tumours with alterations in PIK3CA are sensitive to PI3Kαi and AKTi, while those with alterations in PIK3CA and PTEN are sensitive to AKTi, with enhanced therapeutic benefit when they are combined with inhibitors of ER signalling7,8. This evidence concerns the gene ESR1 and breast cancer.